FOXL2 Mutation Status in Granulosa Theca Cell Tumors of the Ovary

Int J Gynecol Pathol. 2017 Nov;36(6):568-574. doi: 10.1097/PGP.0000000000000377.

Abstract

Ovarian sex-cord stromal tumors that have between 10% and 50% granulosa cells in a prominent fibrothecomatous background have been referred to as granulosa theca cell tumors or mixed granulosa theca cell tumors. The classification and prognosis of these tumors is not clear. Most adult granulosa cell tumors of the ovary harbor a mutation in the FOXL2 gene, whereas fibromas and thecomas lack this mutation. The aim of our study was to assess the FOXL2 mutation status of ovarian granulosa theca cell tumors and to correlate the mutation status with morphologic and clinical characteristics. A FOXL2 mutation was detected in 6 of 12 (50%) granulosa theca cell tumors. Tumors with higher cellularity of granulosa cells were more likely to harbor a FOXL2 mutation as were tumors in which the granulosa cells formed large lobules. No conclusions could be drawn regarding the clinical and prognostic significance of the presence of a mutation given the small number of cases and limited clinical follow-up. Our study shows that half of granulosa theca cell tumors harbor the same FOXL2 mutation that characterizes adult granulosa cell tumors but there is no outcome evidence to guide whether mutation status should alter the classification of the tumor or the management of the patient.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Female
  • Forkhead Box Protein L2 / genetics*
  • Granulosa Cell Tumor / diagnosis
  • Granulosa Cell Tumor / genetics*
  • Granulosa Cell Tumor / pathology*
  • Humans
  • Middle Aged
  • Mutation
  • Ovarian Neoplasms / diagnosis
  • Ovarian Neoplasms / genetics*
  • Ovarian Neoplasms / pathology
  • Ovary / pathology
  • Prognosis
  • Thecoma / diagnosis
  • Thecoma / genetics*
  • Thecoma / pathology

Substances

  • FOXL2 protein, human
  • Forkhead Box Protein L2

Supplementary concepts

  • Granulosa cell tumor of the ovary